Rethink CBD offers the first CRI (Cannabis Research Institute)-endorsed range, guaranteeing best-in-class CBD products in a variety of dosages and formats, all scientifically formulated using the purest quality isolate. With the assurance of seed to shelf integrity, Rethink CBD's specific formulations target health conditions such as anxiousness, sleeplessness, pain and inflammation.
"This is an incredibly exciting partnership that will help us to further build Rethink CBD's portfolio of cannabis-based products. Invenfin's expertise in strategic thinking, business development and marketing will enable us to step up the development of new opportunities for cannabis wellness in South Africa and beyond"
– Martin Coetzer, CEO